Hepatitis E virus IgG seroprevalence in liver transplant patients: A retrospective single-center experience
- PMID: 35782893
- PMCID: PMC9138931
- DOI: 10.14744/hf.2020.2020.0030
Hepatitis E virus IgG seroprevalence in liver transplant patients: A retrospective single-center experience
Abstract
Background and aim: Hepatitis E virus (HEV) may cause chronic liver disease in solid organ transplant recipients. We determined HEV seroprevalence and associated factors in liver transplant recipients.
Materials and methods: Patients followed at the outpatient clinic of liver transplantation between January 2019 and January 2020 were screened retrospectively for HEV serology (HEV immunoglobulin M [IgM] and HEV immunoglobulin G [IgG]).
Results: Of the 150 patients (male/female, 104/46; age, 55.4±13.2 years), anti-HEV IgG was positive in 31 (20.7%), and anti-HEV IgM was negative in all. The mean time after liver transplantation (72 [48%] deceased and 78 [52%] living donors) was 81±78.5 months. Drinking water consisted of carboy and tap water in 88 (58.7%) and 62 patients (41.3%), respectively. Of the patients, 120 (80%) and 30 (20%) lived in urban and rural areas, respectively. On comparison, the difference between positive and negative anti-HEV IgG groups in terms of age, place of birth, water supply, and donor type was statistically significant (p=0.007, p=0.000, p=0.034, and p=0.049, respectively).
Conclusion: HEV seroprevalence was more frequent in liver transplant recipients compared with the normal population. Older age, water supply, and place of birth were risk factors for HEV seroprevalence.
Keywords: Anti-HEV IgG; liver transplantation; seroprevalence.
© Copyright 2021 by Hepatology Forum - Available online at www.hepatologyforum.org.
Conflict of interest statement
Conflict of Interest: The authors have no conflict of interest to declare.
Similar articles
-
Prevalence and characteristics of hepatitis E virus infection in kidney transplant recipients: A single-center experience in Japan.Transpl Infect Dis. 2019 Apr;21(2):e13033. doi: 10.1111/tid.13033. Epub 2018 Dec 14. Transpl Infect Dis. 2019. PMID: 30481402
-
Seroprevalence of Hepatitis E virus infection in children after liver transplantation: A single-center experience in France.Clin Res Hepatol Gastroenterol. 2020 Apr;44(2):174-180. doi: 10.1016/j.clinre.2019.06.002. Epub 2019 Jun 29. Clin Res Hepatol Gastroenterol. 2020. PMID: 31266724
-
High prevalence of anti-HEV antibodies among patients with immunosuppression and hepatic disorders in eastern Poland.Arch Med Sci. 2018 Dec 5;17(3):675-681. doi: 10.5114/aoms.2018.79958. eCollection 2021. Arch Med Sci. 2018. PMID: 34025837 Free PMC article.
-
Hepatitis E seroprevalence and viremia rate in immunocompromised patients: a systematic review and meta-analysis.Liver Int. 2021 Mar;41(3):449-455. doi: 10.1111/liv.14695. Liver Int. 2021. PMID: 33034121
-
Hepatitis E in solid organ transplant recipients: A systematic review and meta-analysis.World J Gastroenterol. 2021 Mar 28;27(12):1240-1254. doi: 10.3748/wjg.v27.i12.1240. World J Gastroenterol. 2021. PMID: 33828397 Free PMC article.
References
-
- Khuroo MS. Study of an epidemic of non-A, non-B hepatitis. Possibility of another human hepatitis virus distinct from post-transfusion non-A, non-B type. Am J Med. 1980;68(6):818–824. - PubMed
-
- European Association for the Study of the Liver EASL Clinical Practice Guidelines on hepatitis E virus infection. J Hepatol. 2018;68(6):1256–1271. - PubMed
-
- Balayan MS, Andjaparidze AG, Savinskaya SS, Ketiladze ES, Braginsky DM, Savinov AP, et al. Evidence for a virus in non-A, non-B hepatitis transmitted via the fecal-oral route. Intervirology. 1983;20(1):23–31. - PubMed
-
- Khuroo MS, Khuroo MS. Hepatitis E: an emerging global disease - from discovery towards control and cure. J Viral Hepat. 2016;23(2):68–79. - PubMed
LinkOut - more resources
Full Text Sources
Miscellaneous